Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Beijing Biotech
Jazz Pharmaceuticals
Bayer
Pfizer
National Institutes of Health Clinical Center (CC)
Actuate Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Eli Lilly and Company
Filamon LTD
AstraZeneca
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Rutgers, The State University of New Jersey
Psyence Australia Pty Ltd
ViroMissile, Inc.
Dana-Farber Cancer Institute
Duke University
AstraZeneca
Tasca Therapeutics
Essen Biotech
MBrace Therapeutics
Azienda Ospedaliero-Universitaria di Parma
Angiex, Inc.
Poseida Therapeutics, Inc.
MacroGenics
Unity Health Toronto
City of Hope Medical Center
Daiichi Sankyo
Takeda
Cue Biopharma
Boehringer Ingelheim
HealthPartners Institute
Second Life Therapeutics
OHSU Knight Cancer Institute
Var2 Pharmaceuticals
City of Hope Medical Center
Mayo Clinic
Degron Therapeutics Co.
Cancer Research UK
Dana-Farber Cancer Institute
Nuvation Bio Inc.